PDCD1 and non-small cell lung carcinoma: The results of our study proved the influence of inhibiting MNK on lung cancer development and highlighted the significance of JDB153 in combination with PD‐1 Ab, which was expected to provide more effective and practicable therapeutic options for NSCLC treatment.